Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2022-08-26 Interim / Quarterly Rep…
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
ANNOUNCEMENT ON INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ANNOUNCEMENT ON INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022' and contains detailed financial data such as sales income, gross profit, net income, earnings per share, assets and liabilities, and cash flow statements for the six-month period ending June 30, 2022. It explicitly states it is the full text of the 2022 Interim Report and complies with listing rules for preliminary announcements of interim results. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or certification. Therefore, this document is a comprehensive interim financial report covering a period shorter than a full fiscal year, which fits the definition of an Interim / Quarterly Report (IR).
2022-08-26 English
Disclosure of Dealings under Rule 22 of the Takeovers Code
Director's Dealing Classification · 95% confidence The document is a Public Disclosure Form dated 26 August 2022, reporting dealings in shares of Yankuang Energy Group Company Limited. It references Rule 22 of the Hong Kong Code on Takeovers and Mergers, indicating it relates to disclosures of share transactions by a party connected with a possible offer. The content details purchases and sales of shares, including quantities and prices, which aligns with insider or director share transactions. There is no indication of a full report, financial statements, or earnings data. The document is short (1740 characters) and focuses on share dealings by a connected party, fitting the definition of Director's Dealing filings rather than a general regulatory announcement or other report types.
2022-08-26 English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Board/Management Information Classification · 95% confidence The document lists the members of the board of directors and their roles and functions, including committee memberships. It is a formal announcement about the composition and structure of the company's board. There is no financial data, no report content, no voting results, no legal proceedings, or other types of filings. This fits the category of Board/Management Information (MANG), which covers announcements of changes or details about the company's board of directors or senior management. The document is short (1414 characters) and purely informational about board members and committees, matching MANG criteria with high confidence.
2022-08-25 English
(1) ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2022&#x3b; (2) CESSATION TO ACT AS THE CHIEF EXECUTIVE OFFICER, THE EXECUTIVE DIRECTOR, THE CHAIRMAN OF THE STRATEGY COMMITTEE AND
Interim / Quarterly Report Classification · 100% confidence The document is an announcement from CStone Pharmaceuticals regarding their unaudited condensed consolidated interim financial results for the six months ended June 30, 2022. It includes detailed financial highlights such as revenue, expenses, and loss for the period, as well as business highlights and operational updates. The presence of actual financial data and analysis for a half-year period, along with comparative figures from the previous year, clearly indicates this is an Interim / Quarterly Report. The document also includes management changes, but the primary focus is on the interim financial results. The length of the document (15,000 characters) and the detailed financial content confirm it is not merely an announcement of a report but the report itself.
2022-08-25 English
Disclosure of Dealings under Rule 22 of the Takeovers Code
Major Shareholding Notification Classification · 95% confidence The document is titled 'Public Disclosure Form' and details securities dealings related to shares of Yankuang Energy Group Company Limited. It references Rule 22 of the Hong Kong Code on Takeovers and Mergers, indicating it is a disclosure of share dealings connected to a possible offer. The content is a tabular report of derivative transactions by a financial trading entity connected to the offeror. There is no indication of a full financial report, earnings release, or management discussion. The document is a regulatory disclosure of share dealings related to a takeover context, fitting the category of Major Shareholding Notification (MRQ) which covers notifications of changes in significant share ownership or dealings related to control. The document length is short and focused on share dealings disclosures, not a report or announcement of a report publication. Therefore, the best classification is MRQ with high confidence.
2022-08-25 English
Disclosure of Dealings under Rule 22 of the Takeovers Code
Director's Dealing Classification · 100% confidence The document is a Public Disclosure Form dated 25 August 2022, detailing securities dealings in the shares of Yankuang Energy Group Company Limited. It references Rule 22 of the Hong Kong Code on Takeovers and Mergers, and provides specifics on share transactions by CICC Financial Trading Limited. The content focuses on insider or related party share transactions rather than financial results, management changes, or regulatory announcements. This matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives or related parties. The document length is short and contains detailed transaction data, not a report or announcement of a report. Therefore, the correct classification is Director's Dealing (DIRS).
2022-08-25 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.